Company news

LENZ Therapeutics, Inc. news in 2021

LENZ Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

December 10, 2021

Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease

December 6, 2021

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

November 16, 2021

Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results

November 9, 2021

Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition

November 3, 2021

Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit

October 20, 2021

Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention

October 11, 2021

Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention

October 4, 2021

Graphite Bio Announces Participation in Upcoming September Investor Conferences

August 29, 2021

Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results

August 11, 2021

Graphite Bio Announces Pricing of Upsized Initial Public Offering

June 23, 2021

Decks in 2021